絞り込み

16640

広告

Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.

著者 Doria C , Leali PT , Solla F , Maestretti G , Balsano M , Scarpa RM
Clin Cases Miner Bone Metab.2016 Sep-Dec ; 13(3):195-199.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (151view , 0users)

Full Text Sources

Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL). RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone.
PMID: 28228781 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード